Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (291-300 of 320) with videos related to

Pageof 32
Sort By:
The Lancet. Oncology|October 3, 2024
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trialJürgen Wolf, Maximilian Hochmair, Ji-Youn Han, et al.
Cell Reports. Medicine|November 9, 2023
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort BXiuning Le, Luis G Paz-Ares, Jan Van Meerbeeck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2025
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief ReportGregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2016
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLCChristian Manegold, Anne-Marie C Dingemans, Jhanelle E Gray, et al.
Cell|August 14, 2018
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor OrganoidsKrijn K Dijkstra, Chiara M Cattaneo, Fleur Weeber, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2015
Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancerWouter W Mellema, Lucie Masen-Poos, Egbert F Smit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2024
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery ProtocolKarlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2020
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 PandemicAnne-Marie C Dingemans, Ross A Soo, Abdul Rahman Jazieh, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2026
Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumabYan Wang, Laura H Bukkems, Johan G C van Hasselt, et al.
The Lancet. Oncology|May 19, 2015
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trialsJoe Y Chang, Suresh Senan, Marinus A Paul, et al.
Pageof 32

Showing results (291-300 of 320) with videos related to

Sort By:
Pageof 32
The Lancet. Oncology|October 3, 2024
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trialJürgen Wolf, Maximilian Hochmair, Ji-Youn Han, et al.
Cell Reports. Medicine|November 9, 2023
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort BXiuning Le, Luis G Paz-Ares, Jan Van Meerbeeck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2025
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief ReportGregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2016
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLCChristian Manegold, Anne-Marie C Dingemans, Jhanelle E Gray, et al.
Cell|August 14, 2018
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor OrganoidsKrijn K Dijkstra, Chiara M Cattaneo, Fleur Weeber, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2015
Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancerWouter W Mellema, Lucie Masen-Poos, Egbert F Smit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2024
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery ProtocolKarlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2020
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 PandemicAnne-Marie C Dingemans, Ross A Soo, Abdul Rahman Jazieh, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2026
Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumabYan Wang, Laura H Bukkems, Johan G C van Hasselt, et al.
The Lancet. Oncology|May 19, 2015
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trialsJoe Y Chang, Suresh Senan, Marinus A Paul, et al.
Pageof 32